Office of Technology Transfer – University of Michigan

Novel adoptive cell transfer immunotherapy against cancer using effector B cells

Technology #6152

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Qiao Li
Managed By
Tiefei Dong
Senior Licensing Specialist, Life Sciences 734-763-5332
Patent Protection
US Patent Pending US-2017-0173180-A1
Publications
In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy.
J Immunol. 2009 Sep 1;183(5):3195-203. doi: 10.4049/jimmunol.0803773. Epub 2009 Aug 10., 2009
Adaptive Transfer of Tumor Reactive B Cells Confers Host T-Cell Immunity and Tumor Regression
Clin Cancer Res. 2011 Aug 1;17(15):4987-95. doi: 10.1158/1078-0432.CCR-11-0207. Epub 2011 Jun 20., 2011

Immunotherapy has shown promising results in the treatment of certain advanced cancers. It is fast becoming an attractive alternative to current anti-cancer treatments. Specifically, the recent development of adoptive cell transfer immunotherapies using T-cells are being tested widely in animal models and cancer patients. While these therapies have solely focused on T-cells, a novel technology involving both effector T and B-cells was found to significantly improve treatment outcomes in animal cancer models.

In vivo sensitized and in vitro activated B-cells augment T-cell based therapy

The current technology utilizes a combination of T-cells along with effector B-cells, uniquely sourced from tumor draining lymph nodes (TDLN) in mice primed with a specific tumor cell. LPS and anti-CD40 are used to activate these purified cells in vitro, followed by inoculation into tumor bearing mice. This combination treatment not only significantly inhibited development of metastasis compared to a T-cell only therapy, but also greatly augmented other anti-cancer therapies, such as radiation and chemotherapy. The B-cells are thought to show improved targeted killing of tumor cells through production of tumor-specific antibodies as well as interactions involving the Fas/FasL and CXCL12/CXCR4 pathways.

Applications

  • Novel anti-cancer immunotherapy
  • Can be used in concert with other anti-cancer therapies, such as radiation and chemotherapy
  • Additional potential applications in treating infectious diseases and neurodegenerative disorders

Advantages

  • Improved efficacy compared to T-cell only based therapies
  • Can augment treatment outcomes for other anti-cancer therapies, such as radiation and chemotherapy